Lithotripsy

Shockwave Medical announced the FDA clearance and full U.S. launch of its peripheral intravascular lithotripsy catheter designed to treat calcified femoropopliteal and below-the-knee peripheral artery disease.

In two trials, OCT-guided PCI demonstrated superiority in imaging endpoints and improved procedural success compared with angiography and fluoroscopy alone, speakers reported.

Shockwave Medical announced that its intravascular lithotripsy catheter for treatment of calcified peripheral artery lesions has been launched commercially in the United States.

Employing intravascular lithotripsy facilitated transcatheter mitral valve replacement in a patient with severe mitral annular and mitral valve leaflet calcification, according to a report on a first-in-human procedure.

Real-world data suggest intravascular lithotripsy appears to be safe with low complications rates during nearly 2 years of follow-up when used for complex calcified coronary lesions, researchers reported.

In a real-world observational study, intravascular lithotripsy was associated with improvement in stenosis in patients with calcified peripheral artery disease, researchers reported at VIVA 22.

ATLANTA — In patients with calcified peripheral artery disease undergoing drug-coated balloon treatment, preparing the vessel with IV lithotripsy conferred better 1-year outcomes vs. preparing it with percutaneous transluminal angioplasty.

In the interim results of the observational DISRUPT PAD III study, intravascular lithotripsy was safe and effective in patients with peripheral artery disease and calcified lesions, researchers reported at VIVA 21.

Three publications in JACC: Cardiovascular Interventions showed how intravascular lithotripsy may benefit patients with severely calcified lesions.

Shockwave Medical announced its intravascular lithotripsy system received premarket approval from the FDA for the treatment of calcified CAD.